跳至主要内容
临床试验/JPRN-UMIN000007216
JPRN-UMIN000007216已完成未知

Efficacy and safety of new drugs for induction, autologous stem cell transplantation, consolidation and maintenance therapy in patients with newly diagnosed symptomatic multiple myeloma: a phase2 study - JSCT-MM12

Japan Study Group for Cell Therapy and Transplantation0 个研究点目标入组 56 人开始时间: 2012年2月2日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
入组人数
56

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
20years-old 至 65years-old(—)
性别
All

入选标准

  • 未提供

排除标准

  • 1. Non-secretory MM and plasmacell leukemia. 2. Patients HIV-positive 3. Severe hepatic dysfunction, severe renal failure, severe cardiac dysfunction, severe pulmonary dysfunction, uncontrolled diabetes, uncontrolled hypertension, and uncontrolled infection. 4. Patients with a history of active malignancy during the past 5 years. 5. Patients with psychiatric disorders such as schizophrenia etc. 6. Pregnant women, pre-menopausal women, and lactating women. 7. History of hypersensitivity to mannitol or boron. 8. Patient was suspected pneumonia(Interstitial pneumonia). Consult a respiratory specialist if necessary 9. Those who are considered as inappropriate to register by attending physicians.

研究者

发起方
Japan Study Group for Cell Therapy and Transplantation

相似试验